TelomEYE Pharmaceuticals is mainly focused on ophthalmology, particularly age-related ophthalmological disorders such as dry eyes, presbyopia, cataracts, glaucoma and macular degeneration. Each of these disorders affects a huge number of people all around the world.
Our novel treatment approach is based on activating TMP and preventing cellular aging of ocular structures. We are proceeding with our clinical work on different phases for these specific disorders as we have seen very promising results from our former studies.
Therapeutic Area | Form | Indication | Code | Discovery & Formula Development | Cell Culture (In Vitro) | Animal Studies (In Vivo) | Histopathology | DNA Analysis | Pre Human Analysis | Human Trials | ||||
Phase 1 | Phase 2 | Phase 3 | ||||||||||||
Ophthalmology | Eye Drop | Presbyopia | TAED017 | |||||||||||
Eye Drop | Dry Eyes | TADE022 | ||||||||||||
Intravitreal Injection | AMD | TAMD022 | ||||||||||||
Eye Drop | Cataract | TACT022 |